- Home
- ANAB vs QNST Comparison
ANAB vs QNST Comparison
Compare ANAB & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- QNST
- Stock Information
- Founded
- ANAB 2005
- QNST 1999
- Country
- ANAB United States
- QNST United States
- Employees
- ANAB N/A
- QNST N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- QNST Business Services
- Sector
- ANAB Health Care
- QNST Consumer Discretionary
- Exchange
- ANAB Nasdaq
- QNST Nasdaq
- Market Cap
- ANAB 1.0B
- QNST 923.2M
- IPO Year
- ANAB 2017
- QNST 2010
- Fundamental
- Price
- ANAB $42.39
- QNST $14.11
- Analyst Decision
- ANAB Buy
- QNST Buy
- Analyst Count
- ANAB 12
- QNST 5
- Target Price
- ANAB $63.80
- QNST $26.40
- AVG Volume (30 Days)
- ANAB 735.4K
- QNST 610.9K
- Earning Date
- ANAB 11-04-2025
- QNST 11-06-2025
- Dividend Yield
- ANAB N/A
- QNST N/A
- EPS Growth
- ANAB N/A
- QNST N/A
- EPS
- ANAB N/A
- QNST 0.18
- Revenue
- ANAB $169,467,000.00
- QNST $1,100,345,000.00
- Revenue This Year
- ANAB $37.52
- QNST $11.18
- Revenue Next Year
- ANAB N/A
- QNST $9.54
- P/E Ratio
- ANAB N/A
- QNST $78.79
- Revenue Growth
- ANAB 196.42
- QNST 43.12
- 52 Week Low
- ANAB $12.21
- QNST $12.98
- 52 Week High
- ANAB $43.31
- QNST $25.50
- Technical
- Relative Strength Index (RSI)
- ANAB 71.33
- QNST 49.70
- Support Level
- ANAB $33.10
- QNST $12.98
- Resistance Level
- ANAB $43.31
- QNST $14.20
- Average True Range (ATR)
- ANAB 2.88
- QNST 0.57
- MACD
- ANAB 0.51
- QNST 0.05
- Stochastic Oscillator
- ANAB 91.49
- QNST 40.36
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.